Chemoprevention of breast cancer with selective oestrogen-receptor modulators

Twenty years ago, a new therapeutic dimension was conceived that not only had the potential to treat and prevent osteoporosis, but to prevent breast and endometrial cancer at the same time. As osteoporosis was known to be caused by oestrogen withdrawal after menopause, whereas breast and endometrial...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Cancer Vol. 7; no. 1; pp. 46 - 53
Main Author Jordan, V. Craig
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.01.2007
Subjects
Anticarcinogenic Agents - pharmacology
Breast cancer
Breast Neoplasms - prevention & control
Chemoprevention
Chemoprevention - methods
Drug therapy
Endometrial Neoplasms - prevention & control
Female
Health aspects
Humans
Methods
Models, Biological
Models, Chemical
Raloxifene Hydrochloride - pharmacology
Receptors, Estrogen - metabolism
Risk factors
Selective Estrogen Receptor Modulators - pharmacology
Tamoxifen - pharmacology
United States
Online AccessGet full text

Cover

More Information
Summary:Twenty years ago, a new therapeutic dimension was conceived that not only had the potential to treat and prevent osteoporosis, but to prevent breast and endometrial cancer at the same time. As osteoporosis was known to be caused by oestrogen withdrawal after menopause, whereas breast and endometrial cancer are caused by unopposed oestrogen action, the new tissue-selective oestrogens and anti-oestrogens, or selective oestrogen-receptor modulators (SERMs), had to recruit new networks to activate or suppress target tissues selectively. New medicines now promise to provide chemoprevention strategies for women at risk for the development of many diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Review-2
ISSN:1474-175X
1474-1768
DOI:10.1038/nrc2048